Introduction {#s1}
============

Childhood acute lymphoblastic leukemia (ALL), the most common cancer in children, can now be cured in approximately 80% of patients \[[@pmed-0050083-b001],[@pmed-0050083-b002]\]. Pharmacogenomics aims to elucidate the genomic determinants of treatment response and why treatment fails to cure the remaining 20% of patients, many of whom have favorable prognostic features \[[@pmed-0050083-b003],[@pmed-0050083-b004]\]. Prior studies have provided insight into the genomic determinants of resistance to several antileukemic agents \[[@pmed-0050083-b005]\], but methodological constraints have precluded such genome-wide studies of in vitro methotrexate (MTX) resistance. This research gap is unfortunate because MTX is widely used in the treatment of many human cancers, including essentially all treatment protocols for newly diagnosed ALL \[[@pmed-0050083-b001]\].

The pharmacokinetics and pharmacodynamics of MTX in ALL cells are well understood, whereas the genomic determinants of the antileukemic effects of MTX remain to be elucidated \[[@pmed-0050083-b006],[@pmed-0050083-b007]\]. Cellular uptake of MTX is mediated by the protein reduced folate carrier \[[@pmed-0050083-b008]\], whereas its efflux is mediated by ATP-binding cassette (ABC), subfamily C 1 (ABCC1) and ABCC4 \[[@pmed-0050083-b009]--[@pmed-0050083-b011]\]. MTX is a tight-binding inhibitor of its primary target, enzyme dihydrofolate reductase (DHFR), which disrupts cellular folate metabolism \[[@pmed-0050083-b012]\]. Within leukemic cells, MTX is metabolized into poly(γ-glutamate) forms (MTXPGs) by an adenosine triphosphate (ATP)-dependent reaction catalyzed by folylpolyglutamate synthetase \[[@pmed-0050083-b013]\]. Compared to their monoglutamate form, MTXPGs are retained longer in cells because they are not readily effluxed by ABC transporters \[[@pmed-0050083-b014],[@pmed-0050083-b015]\]. MTXPGs are more potent inhibitors of other target enzymes such as thymidylate synthetase, glycinamide ribonucleotide transformylase, and aminoimidazole carboxamide transformylase. These enzymes are involved in biosynthetic pathways that are critical for DNA synthesis, DNA repair, and cell replication \[[@pmed-0050083-b014],[@pmed-0050083-b015]\]. Furthermore, accumulation of MTXPG has also been shown to differ among major ALL subtypes \[[@pmed-0050083-b016]\] and to influence treatment response and outcome in childhood ALL \[[@pmed-0050083-b017]--[@pmed-0050083-b019]\].

A more complete understanding of the mechanisms of MTX resistance in ALL cells is needed if new treatment strategies are to be developed for patients whose leukemia is resistant to this important component of ALL chemotherapy \[[@pmed-0050083-b006]\]. Prior genomic studies of ALL chemotherapy resistance have not focused on MTX \[[@pmed-0050083-b005],[@pmed-0050083-b020],[@pmed-0050083-b021]\], because the resistance of primary ALL to MTX cannot be accurately measured by in vitro methods such as the MTT assay \[[@pmed-0050083-b022]\]. For this reason, we used the in vivo response of newly diagnosed patients to initial single-agent MTX treatment, measured as an initial decrease in circulating ALL cells, to quantitate the antileukemic effects of MTX. We then aimed to identify genes whose expression in primary ALL cells is significantly related to the in vivo antileukemic effects of MTX.

Methods {#s2}
=======

Patients and Genetic Characterization of Leukemia Cells {#s2a}
-------------------------------------------------------

A total of 293 children aged 18 y or younger with newly diagnosed ALL, enrolled on the St. Jude Total Therapy XIII and XV protocols, were included in this study ([Figures 1](#pmed-0050083-g001){ref-type="fig"} and [S1](#pmed-0050083-sg001){ref-type="supplementary-material"}). The investigation was approved by the Institutional Review Board at St. Jude Children\'s Research Hospital, and signed informed consent was obtained from parents or legal guardians before enrollment. Patient characteristics (race, sex, age, pretreatment white blood cell count \[WBC~PRE~\], ALL subtype) were assigned by investigators at St. Jude Children\'s Research Hospital. Race, sex, and age were determined by questionnaire; WBC~PRE~, ALL subtype were determined according to the clinical protocol. The diagnosis of ALL was based on morphology, cytochemical staining, and immunophenotyping of blast cells for classification as B cell lineage or T cell lineage, as previously described \[[@pmed-0050083-b023]--[@pmed-0050083-b028]\]. The only patients excluded were those who did not have a diagnosis of ALL, or were aged \< 1 y or \> 18 y, or were given ALL treatment prior to referral to SJCRH.

![CONSORT Flow Chart Describing Patients Enrolled in Randomized Clinical Trials at St. Jude Children\'s Research Hospital, from Which the Current Study Population Was Derived\
The flow chart includes study relevant protocol information for the St. Jude Children\'s Research Hospital Total Therapy Protocols XIIIA, XIIIB, and XV. Specifically, from the population that received ALL treatment according to one of these three protocols, the current study included only patients who received HDMTX as initial therapy. These protocols included a randomization to determine whether patients received HDMTX or not as initial treatment, the infusion time of HDMTX, and whether MP was given after MTX (LDMTX, low-dose methotrexate). Patients with an insufficient number of ALL cells for gene expression analysis were excluded, as were patients with insufficient data on circulating ALL cells to assess response over 3 d.](pmed.0050083.g001){#pmed-0050083-g001}

After stratification for age, WBC~PRE~, immunophenotype, and sex, patients were randomized to receive initial intravenous treatments of high-dose MTX (HDMTX: 1 g/m^2^) either as HDMTX4H (HDMTX by infusion over 4 h; *n* = 108), as HDMTX24H (HDMTX by infusion over 24 h; *n* = 125), or as HDMTX24H+MP (HDMTX by infusion over 24 h plus mercaptopurine \[MP\] 1 g/m^2^ by intravenous injection; *n* = 60). All patients who received allopurinol less than 72 h prior to HDMTX were excluded from the analyses because of potential effects on de novo purine synthesis.

Circulating leukemia cells were measured before therapy (WBC~PRE~) and at day 3 following start of HDMTX treatment (WBC~Day3~), prior to the administration of other antileukemic agents. Leukocyte counts were determined with a Coulter counter (model F_STKR; Coulter, Hialeah, Florida, United States).

Isolation of ALL Blasts from Bone Marrow Aspirate {#s2b}
-------------------------------------------------

ALL blasts were obtained from bone marrow aspirates at diagnosis and 42--44 h following treatment. Samples consisted of 5--10 ml of bone marrow collected in syringes containing 800 units of heparin and kept on ice until processed. Leukemic cells were obtained by density separation over a Ficoll-Hypaque gradient and washed three times with a solution of HEPES, Hanks buffered solution, and heparin, as previously described in detail \[[@pmed-0050083-b018]\].

RNA Extraction and Gene Expression Profiling of Diagnostic Bone Marrow ALL Cells {#s2c}
--------------------------------------------------------------------------------

Of the 293 patients treated with up-front HDMTX, 161 had sufficient diagnostic ALL cells for gene expression analysis (i.e., had sufficient leukemia cells in their diagnostic bone marrow aspirates to permit RNA isolation from 5 × 10^6^ to 1 × 10^7^ ALL cells). High-quality total RNA was extracted with TriReagent (MRC, Cincinnati, Ohio, United States) from cryopreserved mononuclear cell suspensions from bone marrows at diagnosis. Total RNA was processed and hybridized to the HG-U133A oligonucleotide microarray (Affymetrix, Santa Clara, California, United States). This array contains 22,215 gene probe sets, representing approximately 12,357 human genes, plus approximately 3,820 expressed sequence tag clones with unknown function \[[@pmed-0050083-b029]\]. Following removal of probe sets with \>95% absent calls, 13,488 probe sets remained. Scaled expression values of all probe sets were logarithmically transformed to stabilize variance.

Additional information on the microarray methods and results can be found at <http://www.stjuderesearch.org/data/>.

Determination of MTX Polyglutamylated Metabolites in Bone Marrow ALL Cells 42--44 Hours Post-treatment {#s2d}
------------------------------------------------------------------------------------------------------

Intracellular MTXPGs were extracted from 42- to 44-h post-treatment bone marrow ALL cells kept in a buffered solution (Tris, EDTA, and 2-mercaptoethanol \[pH 7.8\]) by first boiling (100 °C for 10 min), then stored frozen at −80 °C until analysis. The HPLC separation and the radioenzymatic quantitation of MTX and six polyglutamylated metabolites (MTXPG~2--7~) were performed as previously described \[[@pmed-0050083-b030],[@pmed-0050083-b031]\]. These MTXPG measurements were available for 230 patients. All results were expressed as picomoles of MTX or MTXPG per 10^9^ cells.

Statistical Analysis and Bioinformatics {#s2e}
---------------------------------------

MTX responses as measured by WBC~Day3~, WBC~PRE~, and MTXPG values were logarithmically transformed to normalize their respective distributions. The Pearson correlation test was applied in order to determine the association between WBC~Day3~ and ALL subtype, MTXPG, and WBC~PRE~. The difference between WBC~PRE~ and WBC~Day3~, WBC~ΔDay3~ (the WBC residual based on the linear regression of log\[WBC~PRE~\] change to log\[WBC~Day3~\] ) was determined by taking the residuals of the linear regression model of WBC~Day3~ versus WBC~PRE~, which was available for 293 patients. Specifically, MTX response is defined as:

We indicated "MTX poor response" and "MTX good response" in [Figures 2](#pmed-0050083-g002){ref-type="fig"} and [3](#pmed-0050083-g003){ref-type="fig"} according to the cutoff for good responders (WBC~ΔDay3~ \< −0.14) and poor responders (WBC~ΔDay3~ \> 0.14), based on the bottom and top quartile of 293 patients.

![Scatterplot of WBC~Day3~ versus WBC~PRE~\
This plot illustrates the leukemia cell count on day 3 (WBC~Day3~) after initial HDMTX treatment versus the pretreatment leukemia cell count (WBC~PRE~) at diagnosis in 293 patients. The solid line indicates the linear regression, and the dotted line the 95% confidence interval with *p* \< 0.0001, *r* = 0.76, Spearman rank correlation, and *p* \< 0.0001, *r* = 0.79, Pearson correlation.](pmed.0050083.g002){#pmed-0050083-g002}

![Hierarchical Clustering of Genes Discriminating MTX Response (WBC~ΔDay3~)\
Hierarchical clustering using the top 50 most discriminant gene probe sets ([Table S3](#pmed-0050083-st003){ref-type="supplementary-material"}) discriminating MTX response in 161 patients. Each column represents an ALL sample labeled with red circles for MTX poor responders (*n* = 40, top quartile of WBC~ΔDay3~) and with green circles for MTX good responders (*n* = 40, bottom quartile of WBC~ΔDay3~). Unlabeled patients are intermediate MTX responders. Each row represents a probe set labeled with the gene symbol. The "heat map" indicates high (red) or low (green) level of expression according to the scale shown.](pmed.0050083.g003){#pmed-0050083-g003}

Data were available for 161 patients on both WBC~ΔDay3~ and gene expression in diagnostic bone marrow leukemia cells ([Figure S1](#pmed-0050083-sg001){ref-type="supplementary-material"}). The association between each individual probe set and WBC~ΔDay3~ was determined using the Pearson correlation test. Gene probe sets were rank-ordered by their *p*-values. Final gene probe sets were selected based on a false discovery rate (FDR) cutoff of 1.5%.

For each patient, we computed a gene expression profile using the weighted average of the expression signals of top selected genes. The Pearson correlation coefficient between each gene\'s expression and WBC~ΔDay3~ was used as the weight. This weighted average of expression signals was used as the summary of the top gene expression profile for each patient. Specifically, the gene expression profile was computed according to the following formula:

Where *j* = 1 ... 50 top selected gene probe sets as listed in [Table S3](#pmed-0050083-st003){ref-type="supplementary-material"}, and weights were determined as the correlation coefficients as listed in the same table.

We compared the top 50 gene profile with the top 100 gene profile; the correlation coefficient was 0.989 (*p* \< 0.001, Pearson correlation test). These tests were performed using standard statistical functions in R software.

We tested 37 GenMAPP pathways and 319 Gene Ontology--biological process (GO--BP) gene groupings for association with WBC~ΔDay3~ using the "globaltest" method \[[@pmed-0050083-b032]\] implemented in the R Bioconductor package \[[@pmed-0050083-b033]\]. This test was used to infer over-representation of specific biological pathways, and the "geneplot" function was applied to plot the importance of selected genes with default parameters. Multiple testing was adjusted using the Bonferroni method and the FDR according to Storey and Tibshirani \[[@pmed-0050083-b034]\].

Cell Cycle Distribution {#s2f}
-----------------------

The percentage of ALL cells in S-phase was determined in diagnostic bone marrow aspirates from patients for whom an adequate number of cells were available (*n* = 154). Propidium iodide--stained DNA content was measured by flow cytometry using the Coulter EPICS V flow cytometer (Coulter Electronics, Hialeah, Florida, United States), and the computer program ModFit (Verity Software House, Verity, Topsham, Maine, United States) was used to calculate the percentages of cells in G~0~/G~1~, S, and G~2~/M phase.

Treatment Outcome Analysis {#s2g}
--------------------------

The duration of disease-free survival (DFS) was defined as the time from diagnosis until the date of leukemia relapse (event), or the last follow-up (censored). Second malignancies and death due to other reasons were censored at the time of occurrence. Treatment outcome was available in 136 patients of the 293 patients treated with HDMTX with WBC~PRE~ and WBC~Day3~ measured. Of note, patients treated on protocol T15 were excluded because of short follow-up. Time was also censored at the last follow-up date if no failure was observed. Single-variable analysis using Cox proportional hazards regression, as modified by Fine and Gray \[[@pmed-0050083-b035]\] was used to estimate the relative risk of an event. Significant associations from the single variable analyses were further evaluated in a multiple variable analysis, which included risk classification, age, lineage, and ALL subtype in addition to WBC~ΔDay3~ and the top 50 gene expression profile. DFS curves were calculated by reversing the cumulative incidence curve, where MTX poor responders represent the top quartile, intermediate responders the middle two quartiles, and good responders the bottom quartile.

Results {#s3}
=======

Relation among WBC~Day3,~ WBC~PRE~, Treatment, ALL Subtype, and MTX Metabolism {#s3a}
------------------------------------------------------------------------------

Patient characteristics (race, sex, age, WBC~PRE~, ALL subtype) were similar among patients randomly assigned to receive HDMTX4H, HDMTX24H, or HDMTX24H+MP (*p* \> 0.13, [Figure S2](#pmed-0050083-sg002){ref-type="supplementary-material"}). Furthermore, there was no difference in WBC~Day3~ among the three randomized treatment groups ([Table 1](#pmed-0050083-t001){ref-type="table"}). The lack of differences among treatment groups coupled with our previous findings of minimal de novo purine synthesis (DNPS) inhibition and antileukemic effects of a single dose of intravenous MP \[[@pmed-0050083-b036]\], allowed us to analyze patients treated with HDMTX4H, HDMTX24H, and HDMTX24H+MP as a single group, to enhance the statistical power of our analyses.

###### 

Patient Characteristics Were Not Different among the HDMTX Treatment Groups

![](pmed.0050083.t001)

WBC~Day3~ was significantly lower than WBC~PRE~ (*n* = 293, *p* \< 0.0001) and was highly correlated with WBC~PRE~ (*p* \< 0.0001, *r* = 0.79, [Figure 2](#pmed-0050083-g002){ref-type="fig"}). Therefore, to remove the effect of the pretreatment leukemia burden (WBC~PRE~) we used the WBC~ΔDay3~ corresponding to the residuals from the linear regression model of WBC~Day3~ versus WBC~PRE~ ([Figure 2](#pmed-0050083-g002){ref-type="fig"}). As indicated in [Figure S3](#pmed-0050083-sg003){ref-type="supplementary-material"}, the histogram of the residuals approximates a normal distribution, in contrast to the skewed distribution of percentage drop in WBC count from diagnosis to day 3 (WBC~%drop~; *p* = 0.1 versus *p* \< 0.001, Kolmogorov-Smirnov test). There was a statistically significant association between WBC~ΔDay3~ and polyglutamylated MTX levels (MTXPG~2--7~) in ALL cells (*n* = 230, *p* = 0.0001, *r* = −0.25, [Figure 4](#pmed-0050083-g004){ref-type="fig"}), with higher MTXPG~2--7~ associated with greater antileukemic effect. There was not a significant relation between WBC~ΔDay3~ and ALL subtype (*n* = 293, *p* = 0.07).

![Scatterplot of WBC~ΔDay3~ Versus Level of Total MTXPGs\
There is a significant correlation of WBC~ΔDay3~ with the total MTXPG level in ALL cells from 230 patients (i.e., a higher total MTXPG concentration is associated with a better in vivo MTX response) (*p* = 0.0001, *r* = −0.25, Pearson correlation).](pmed.0050083.g004){#pmed-0050083-g004}

Relation among WBC~ΔDay3~, Gene Expression, and Pathway Analysis {#s3b}
----------------------------------------------------------------

Our analyses of antileukemic effects after in vivo MTX treatment and gene expression in pretreatment ALL cells identified the 50 most significant gene probe sets that were associated with antileukemic effect of MTX (WBC~ΔDay3~, [Figure 3](#pmed-0050083-g003){ref-type="fig"}). The FDR was less than 1.5% for these gene probe sets, and each gene had a Pearson correlation coefficient higher than 0.3 or lower than −0.3 and a *p*-value less than 0.001. Among these genes, the expression patterns for 21 were positively and 29 were negatively related to MTX response. Genes significantly associated with MTX response included those involved in nucleotide metabolism (*thymidylate synthetase* \[*TYMS*\] and *CTP synthase* \[*CTPS*\]), cell proliferation and apoptosis (*B-cell CLL/lymphoma 3* \[*BCL3*\], *centromere protein F* \[*CENPF*\], *cell division cycle 20* \[*CDC20*\], *abnormal spindle--like* \[*ASPM*\], *transforming, acidic coiled-coil containing protein 1* \[*TACC1*\], and *Fas apoptotic inhibitory molecule 3* \[*FAIM3*\]), and several genes implicated in DNA replication and repair (*DNA polymerase delta, subunit 3* \[*POLD3*\], *replication protein A3* \[*RPA3*\], *ribonuclease H2, subunit A* \[*RNASEH2A*\], *GINS complex subunit 2* \[*GINS2*\], *ribonucleotide reductase M1* \[*RRM1*\], *H2A histone family, member X* \[*H2AFX*\], and *flap structure-specific endonuclease 1* \[*FEN1*\]).

To gain more insight into the molecular and cellular pathways related to MTX response, the global test analysis was used to determine whether the gene expression profile of different pathways retrieved from the GO--BP or GenMAPP database, were significantly associated with the antileukemic effect of MTX. As listed in [Table S1](#pmed-0050083-st001){ref-type="supplementary-material"}, a significant association was found between WBC~ΔDay3~ and various biological pathways including those involved in cell cycle regulation, DNA repair and replication, or nucleotide metabolism. To further illustrate the influence of individual genes on the antileukemic effects of MTX within the nucleotide biosynthesis pathway, the "gene plot" output was used. As depicted in [Figure S4](#pmed-0050083-sg004){ref-type="supplementary-material"}, three (*TYMS, DHFR,* and *CTPS*) of the ten genes belonging to the nucleotide biosynthesis pathway were most strongly negatively associated with the MTX antileukemic effect (WBC~ΔDay3~).

Cellular Proliferation and MTX In Vivo Response {#s3c}
-----------------------------------------------

We were able to determine both the percentage of cells in S-phase of the cell cycle and gene expression in 154 patients (these are by ALL subtype: B-lineage hyperdiploid, *n* = 40; B-lineage other, *n* = 47; *E2A-PBX1*, *n* = 14; T-ALL, *n* = 21; *TEL-AML1*, *n* = 32; *BCR-ABL*, *n* = 4; *MLL-AF4*, *n* = 2). There were no significant differences in the percentage of cells in S-phase among different ALL subtypes (*p* = 0.10, Kruskal-Wallis test). The percentage of cells in S-phase of the cell cycle was positively correlated with expression of genes involved in nucleotide biosynthesis *TYMS* (*r* = 0.59, *p* \< 0.001), *DHFR* (*r* = 0.39, *p* \< 0.001), and *CTPS* (*r* = 0.21, *p* = 0.009) ([Figure S5](#pmed-0050083-sg005){ref-type="supplementary-material"}A, [Table 2](#pmed-0050083-t002){ref-type="table"}), with expression of *TYMS* being the best marker of cell proliferation. The percentage of cells in S-phase was significantly correlated with MTX response measured as WBC~ΔDay3~, with the higher percentage in S-phase associated with a better response (WBC~ΔDay3~, *r* = −0.20, *p* = 0.013; [Figure S5](#pmed-0050083-sg005){ref-type="supplementary-material"}B, [Table 2](#pmed-0050083-t002){ref-type="table"}). The association with percentage S-phase was similar to the top 50 gene expression profile (*r* = −0.57 *p* \< 0.001; [Figure S5](#pmed-0050083-sg005){ref-type="supplementary-material"}C, [Table 2](#pmed-0050083-t002){ref-type="table"}). In contrast, the percent drop in WBC count was not significantly related to percentage of cells in S-phase (WBC~%drop~, *r* = 0.034, *p* = 0.67; [Table 2](#pmed-0050083-t002){ref-type="table"}).

###### 

Pearson Correlation of Selected Biological and Response Parameters with Percentage of Cells in S-Phase

![](pmed.0050083.t002)

Relation between Disease-Free Survival and Expression of *CTPS, TYMS*, *DHFR,* MTX Response (WBC~%drop~ and WBC~ΔDay3~), and Top 50 Gene Expression Profile {#s3d}
-----------------------------------------------------------------------------------------------------------------------------------------------------------

The median follow-up of patients for this analysis was 9.1 y from diagnosis, comprising patients enrolled in St. Jude Total Therapy XIII protocol (*n* = 136). WBC~ΔDay3~, and *TYMS* and *DHFR* expression, were related to DFS according to Cox proportional hazards regression analyses that compared patients who remained in continuous complete remission with those who relapsed during the follow-up period. The univariable analysis of variables potentially related to DFS revealed significance for expression of *TYMS* (hazard ratio \[HR\] = 0.6; *p* = 0.008), expression of *DHFR* (HR = 0.41; *p* = 0.015); MTX response (WBC~ΔDay3~, HR = 21.5; *p* \< 0.001), and the top 50 gene expression profile (HR = 1.09; *p* = 0.02; [Table 3](#pmed-0050083-t003){ref-type="table"}), but not for the expression of *CTPS* or the WBC~%drop~.

###### 

Univariable Hazard Analysis of the Risk of Relapse with Variables Related to Initial In Vivo MTX Response and Multivariable Cox Proportional Hazard Analyses Each Including Known Prognostic Factors (i.e., ALL Subtype, Age at Diagnosis, Risk Group)

![](pmed.0050083.t003)

Patients with the best MTX response (i.e., bottom quartile of the residual WBC~ΔDay3~) had significantly better 5-y DFS compared to patients with the worst response (top quartile) (DFS ± SE 96.9% ± 3.1% versus 81.4% ± 7%, *p* = 0.033 for quartiles compared; [Figure 5](#pmed-0050083-g005){ref-type="fig"}A). Likewise, patients with a gene expression profile indicative of a good MTX response (bottom quartile of the gene expression profile) had significantly better 5-y DFS compared to patients with a gene expression profile indicative of poor MTX response (top quartile of the gene expression profile) (5-y DFS ± variance: 87.5% ± 6.9% versus 72% ± 9.2%, *p* = 0.019 for quartiles compared; [Figure 5](#pmed-0050083-g005){ref-type="fig"}B). Patients with higher *TYMS* or *DHFR* expression (i.e., top quartile of the expression level) had significantly better 5-y DFS compared to patients with lower *TYMS* or *DHFR* expression (i.e., bottom quartile of the expression level) (5-y DFS ± variance: 87.9% ± 5.8% versus 72.7% ± 7.9%, *p* = 0.024 for *TYMS* and 93.5% ± 4.5% versus 69% ± 8.1%, *p* = 0.041 for *DHFR* for quartiles compared; [Figure 5](#pmed-0050083-g005){ref-type="fig"}C).

![Kaplan-Meier Plots of Disease Relapse Categorized by WBC~ΔDay3~, *TYMS*, and Top 50 Gene Profile\
(A) MTX response is categorized by WBC~ΔDay3~ MTX good responders (i.e., bottom quartile, *n* = 28), intermediate (*n* = 67), and poor (i.e., top quartile, *n* = 41) among 293 patients.\
(B) Top 50 gene expression profile is categorized by top 25% (gene profile for good responder, *n* = 20), intermediate (*n* = 53), and bottom 25% (gene profile for poor responder, *n* = 19).\
(C) Proliferation index is categorized by *TYMS* expression top 25% (high proliferation index, *n* = 27), intermediate (*n* = 47) and bottom 25% (low proliferation index, *n* = 18). For *TYMS* and top 50 gene profile, categorization was done among the 161 patients who had ALL cell gene expression data available.](pmed.0050083.g005){#pmed-0050083-g005}

Furthermore, multivariable Cox regression analysis ([Tables 3](#pmed-0050083-t003){ref-type="table"} and [S2](#pmed-0050083-sg002){ref-type="supplementary-material"}) that also included the conventional National Cancer Institute ALL risk criteria (i.e., ALL subtype, age, and WBC at diagnosis) revealed significance for MTX response (WBC~ΔDay3~, HR = 22.6; *p* = 0.0046), and the expression of *TYMS* (HR = 0.58; *p* = 0.044) and *DHFR* (HR = 0.31; *p* = 0.019). The top 50 gene expression profile did not reach statistical significance in predicting relapse in the overall population when other known risk factors were included, although the trend remained evident (*p* = 0.08, [Tables 3](#pmed-0050083-t003){ref-type="table"} and [S2](#pmed-0050083-sg002){ref-type="supplementary-material"}).

Discrimination of MTX Response Using the Top 50 Gene Expression Profile and Assessment in an Independent Validation Cohort {#s3e}
--------------------------------------------------------------------------------------------------------------------------

In an independent test set of 18 additional patients who received initial HDMTX according to the St. Jude Total Therapy XV protocol, we performed gene expression analysis at diagnosis and determined WBC (ALL cell) count at diagnosis and on day 3. The gene expression profile of the top 50 genes was significantly related to the residual WBC~ΔDay3~ in this patient cohort (top 50 gene profile, *p* = 0.0065, *r* = 0.62, Pearson correlation; [Figure 6](#pmed-0050083-g006){ref-type="fig"}A), thus validating the gene expression profile as predictive of the MTX response in an independent cohort of patients.

![Model Performance in an Independent Test Set of Patients\
Relation between the in vivo MTX response (WBC~ΔDay3~) and top 50 gene expression profile (*p* = 0.0065, *r* = 0.62, Pearson correlation) for the independent validation cohort (*n* = 18). Relation between (B) the predicted log(WBC~Day3~) using either the linear model function or (C) the median percentage drop determined in 293 patients (mean difference = 0.1812946. *p* = 0.0025, paired *t*-test). The regression lines in graphs (B) and (C) are based on intercept equal to zero and slope equal to one.](pmed.0050083.g006){#pmed-0050083-g006}

Additionally, we predicted the WBC~Day3~ after initial MTX treatment based on the known WBC~PRE~ in these 18 newly enrolled patients. For that, we used either the WBC~ΔDay3~ linear regression function or the median WBC~%drop~ developed in the original test cohort of 293 patients. The sum of the differences between the observed and the predicted WBC~Day3~ squared was 1.042 using the WBC~ΔDay3~ linear regression model and 3.35 using the median WBC~%drop~. The observed WBC~Day3~ values are significantly closer to the predicted values using WBC~ΔDay3~ ([Figure 6](#pmed-0050083-g006){ref-type="fig"}B) than those based on WBC~%drop~ ([Figure 6](#pmed-0050083-g006){ref-type="fig"}C; *p* = 0.0025, paired *t*-test), thereby further indicating that WBC~ΔDay3~ is a more accurate measure of in vivo MTX response than WBC~%drop~.

Discussion {#s4}
==========

The current studies have identified genes that are expressed at a significantly different level in acute lymphoblastic leukemia cells of patients who exhibit a poor in vivo response to HDMTX. High-throughput genomic approaches to assess the expression levels of RNA transcripts in cancer cells are providing new insights into pathogenesis, classification, diagnosis, stratification, and prognosis of many human cancers \[[@pmed-0050083-b023],[@pmed-0050083-b037]--[@pmed-0050083-b039]\]. The drug resistance and gene expression profiles of leukemia cells have also been used to identify genes related to the sensitivity of ALL cells to several antileukemic agents and to forecast differences in treatment response \[[@pmed-0050083-b005],[@pmed-0050083-b020],[@pmed-0050083-b021]\]. These findings have also revealed novel targets for the discovery of new agents to reverse drug resistance, such as our prior discovery of *MCL1* overexpression in glucocorticoid-resistant ALL \[[@pmed-0050083-b005]\], and the subsequent discovery that rapamycin can down-regulate *MCL1* expression and increase sensitivity of leukemia cells to dexamethasone \[[@pmed-0050083-b037],[@pmed-0050083-b040]\]. However, prior to the current study, there has not been a comprehensive analysis of genes related to the antileukemic effects of MTX in primary leukemia cells.

We therefore evaluated MTX response in vivo after initial therapy, because this is the only possible time to assess the antileukemic effects of MTX as a single agent in patients and because there are no reliable in vitro methods. Thus, our study focused on treatment-naive ALL, and assessed de novo resistance. This revealed that WBC~ΔDay3~ is a superior measure of in vivo MTX response when compared to the percentage drop in leukemia cells (i.e., WBC~%drop~), and that WBC~ΔDay3~ was predictive of long-term DFS. Furthermore, the difference in survival cannot simply be explained by differences in MTX systemic exposure ([Figure S6](#pmed-0050083-sg006){ref-type="supplementary-material"}).

To better understand the biological basis underlying MTX response in ALL cells, we used an unbiased genome-wide approach to identify genes whose expression in primary leukemia cells in vivo was significantly related to WBC~ΔDay3~. This process revealed 48 genes and two cDNA clones that are highly related to the in vivo MTX response (WBC~ΔDay3~), even after adjusting for MTXPG accumulation (*n* = 230) ([Table S3](#pmed-0050083-st003){ref-type="supplementary-material"}). Among those genes significantly associated with MTX response were genes involved in nucleotide metabolism (*TYMS* and *CTPS*), cell proliferation and apoptosis (*BCL3, CDC20, CENPF,* and *FAIM3*), and DNA replication or repair (*POLD3, RPA3, RNASEH2A, RPM1,* and *H2AFX*). The antileukemic effects of MTX involve inhibition of purine and pyrimidine synthesis, and the current findings indicate that interindividual differences in nucleotide synthesis influence the in vivo antileukemic effects of MTX. This finding was confirmed by a global test analysis that identified the nucleotide biosynthesis pathway as one of the most discriminating biological pathways related to MTX response. Significance of the global test was largely explained by three key genes (*TYMS*, *DHFR*, and *CTPS*) belonging to the nucleotide biosynthesis pathway.

Our analysis also showed that low expression of *DHFR, TYMS,* and *CTPS* was significantly correlated with poor in vivo MTX response \[[@pmed-0050083-b006],[@pmed-0050083-b041],[@pmed-0050083-b042]\]. It has been shown that *DHFR, TYMS,* and *CTPS* expression is associated with critical biological processes such as DNA synthesis and cell proliferation \[[@pmed-0050083-b043],[@pmed-0050083-b044]\], a finding consistent with low expression of these genes reflecting a decrease in the number of ALL cells in S-phase. As MTX selectively affects cells in the S-phase of the cell cycle \[[@pmed-0050083-b007],[@pmed-0050083-b044],[@pmed-0050083-b045]\], it is likely that low expression of these genes explains the observed association with MTX response. To support this hypothesis, we showed that the percentage of leukemia cells in the S-phase was strongly correlated with *DHFR*, *TYMS*, and *CTPS* expression and with the MTX in vivo response ([Figure S5](#pmed-0050083-sg005){ref-type="supplementary-material"}, [Table 2](#pmed-0050083-t002){ref-type="table"}). This finding does not preclude the possibility that genetically determined high *TYMS* expression in ALL cells is associated with a worse prognosis in ALL, as we have previously reported \[[@pmed-0050083-b046]\]. High *TYMS* expression in the current study was related to higher cell proliferation, whereas higher constitutive *TYMS* expression is due to a genetic polymorphism in the *TYMS* promoter region. After remission is achieved, higher *TYMS* expression due to the promoter polymorphism would connote a worse prognosis due to higher levels of the MTX target, thymidylate synthase, independent of cellular proliferation rates.

Our current data showed that low cell proliferation levels, in addition to our measure of in vivo MTX response, is an important ALL cell characteristic related to worse outcome. This result is in agreement with those of a previous study that found treatment-naïve blasts with a low proliferation rate are more resistant to several anticancer drugs in vitro \[[@pmed-0050083-b047]\]. In the current study, the gene expression profile predicting MTX response was not associated with overall disease outcome after adjusting for other known prognostic variables in the entire study population (*p* = 0.08), but was significantly related to DFS within high-risk patients (*p* = 0.014). Leukemia cells of patients with high-risk ALL may intrinsically have a higher potential for poor MTX response (e.g., because of oncogenic gene fusions), in contrast to lower-risk patients whose ALL cells may acquire resistance mechanisms during the 2--3 y of therapy. Further, it is possible that patients with high-risk leukemia may be more prone to acquire resistance during therapy for various reasons (e.g., greater genetic instability in their ALL cells).

Interestingly, other known folate metabolism genes were not among the top genes, suggesting that expression of the known folate metabolism genes in pretreatment ALL cells is less important in causing de novo MTX resistance than previously thought. It may well be that these folate pathway genes are important for the acquired drug resistance that emerges during MTX treatment. It is also plausible that expression or function of these proteins is not reflected by the level of their mRNA expression in ALL cells. These possibilities merit further investigation, which is beyond the scope of the current work.

Defining the genomic determinants of ALL resistance to individual antileukemic agents is essential if the pharmacogenomics of drug resistance are to be elucidated, because the current and prior studies have shown that genes discriminating drug resistance in ALL are drug specific \[[@pmed-0050083-b005],[@pmed-0050083-b048]\]. To assess whether the genes we identified as related to de novo MTX resistance reflect a global resistance phenotype versus a MTX-specific effect, we compared the previously reported gene expression profiles for ALL resistance to PVAD (prednisone, vincristine, asparaginase, and daunorubicin), with the top 50 genes discriminating MTX response in the current study. This comparison revealed no overlap in the genes related to MTX resistance and the 124 genes related to prednisone, vincristine, asparaginase or daunorubicin PVAD resistance \[[@pmed-0050083-b005]\]. This result indicates that genes identified in the current study are not a marker of general drug resistance or a global predictor of survival, rather they are specific to MTX (or perhaps other antifolates, but not all ALL chemotherapy). Furthermore, we applied our MTX gene expression profile to the publicly available German/Dutch dataset \[[@pmed-0050083-b005]\], and documented that the MTX gene expression profile is not related to prednisolone sensitivity in this independent patient cohort (unpublished data).

Among the 50 genes that were expressed at a significantly different level in leukemia cells of MTX good responders versus poor responders, 29 were overexpressed in the MTX poor- responders. It is plausible that these overexpressed genes would be candidate targets for small molecules or other strategies to down-regulate their function, as a means to modify MTX response. Such a strategy has already proven successful in finding agents to modify the sensitivity of ALL cells to steroids \[[@pmed-0050083-b040]\], and it is plausible that specific inhibitors of genes overexpressed in leukemia cells resistant to MTX could be viable targets for modulating the antileukemic effects of MTX. Likewise, strategies to invoke the expression of genes that are underexpressed in MTX poor responders could be tested for their ability to modulate MTX sensitivity.

The current study is the first, to our knowledge, to identify genes whose expression is related to in vivo MTX response in patients with newly diagnosed ALL. Our data provide new insights into the genomic basis of interpatient differences in MTX response and point to new strategies for overcoming de novo MTX resistance in childhood ALL. In addition, our data indicate that early treatment response to MTX is a significant prognostic indicator for long term DFS in children with ALL.
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###### Flow Diagram of Data and Methods Used

Gray boxes indicate data used for the analyses, white boxes intermediate data, shaded boxes data analysis method used, and *n* the number of patients.

(657 KB PDF)

###### 

Click here for additional data file.

###### Box Plot of WBCDay3 Versus MTX Treatment Group

The three initial treatment groups with HDMTX were not different in their WBCDay3 (HDMTX24H, *n* = 125; HDMTX24H+MP, *n* = 60; HDMTX4H, *n* = 108, Welch two-sample *t*-test).

(16 KB PDF)

###### 

Click here for additional data file.

###### Histogram of WBC Change and WBC Residuals

Shown are the distributions of 293 patients for (A) WBC~LogChange~ that is defined as log(WBC~PRE~) minus log(WBC~Day3~), *p* = 0.04, i.e., is significantly different from a normal distribution; and (B) WBC~ΔDay3~ that is the residuals of the (log\[WBC~Day3~\] with log\[WBC~PRE~\]) linear regression, *p* = 0.10, i.e., is not significantly different from a normal distribution.

(653 KB PDF)

###### 

Click here for additional data file.

###### Gene Plot of the Gene Ontology Nucleotide Biosynthesis Pathway

The gene plot gives a bar and a reference line for each gene probe set categorized for this pathway. The bar indicates the influence of each probe set on the correlation with MTX response (WBC~ΔDay3~). If the height of the bar exceeds the reference line the probe set is significantly related to MTX response. Marks indicate the standard deviations by which the bar exceeds the reference line. Red indicates gene probe sets with a positive correlation and green indicates gene probe sets with a negative correlation with MTX response.

(340 KB PDF)

###### 

Click here for additional data file.

###### Scatterplot of *TYMS* and *DHFR* Expression, WBC~%drop~, WBC~ΔDay3~, and Top 50 Gene Profile Versus Percentage of Leukemia Cells in S-Phase

Shown are the scatterplots for 154 patients correlating percentage of leukemia cells in S-phase with (A) the expression of *TYMS* and *DHFR* (respectively, *r* = 0.59; *p* \< 0.001; *r* = 0.39, *p* \< 0.001, Pearson correlation); and (B) for WBC~%drop~ and the residual WBC~ΔDay3~ of the WBC change (respectively, *r* = 0.034, *p* = 0.67; *r* = −0.20, *p* = 0.013, Pearson correlation); and (C) the top 50 gene expression profile (*r* = −0.57, *p* \< 0.001, Pearson correlation).

(163 KB PDF)

###### 

Click here for additional data file.

###### MTX Systemic Exposure Was Not Different among Responder Groups

There was no difference (*p* = 0.82) in MTX~AUC~ (methotrexate area under the curve, representing MTX systemic exposure) in the groups (MTX good responder \[GR\] versus MTX intermediate \[IR\] versus MTX poor responder \[PR\]). We used the same cutoff for MTX response (WBC~ΔDay3~) as in [Figure 3](#pmed-0050083-g003){ref-type="fig"}. Therefore, the difference in survival cannot be explained by the difference in MTX~AUC~.

(59 KB PDF)

###### 

Click here for additional data file.

###### The Top Ten GenMAPP (of 37) (A) and GO--BP (of 319) (B) Pathways Associated with WBC~ΔDay3~

The column titled "probe-set correlations with WBC~ΔDay3~" indicates whether most probe sets in the pathway have a positive correlation, a negative correlation or a mixture of positive and negative correlations with WBC~ΔDay3~.

(56 KB DOC)

###### 

Click here for additional data file.

###### Multivariable Cox Proportional Hazard Analysis of the Risk of Relapse

Individual factors related to MTX response are highlighted in gray (i.e., WBC~ΔDay3~, TYMS, DHFR, top 50 gene profile), each including known prognostic factors (i.e., ALL subtype, age at diagnosis, risk group).

(57 KB DOC)

###### 

Click here for additional data file.

###### The Top 50 Probe Sets Associated with WBC~ΔDay3~

(105 KB DOC)

###### 

Click here for additional data file.

###### CONSORT Checklist

(64 KB DOC)

###### 

Click here for additional data file.
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MIAME-compliant primary microarray data are available through the Gene Expression Omnibus (NCBI) at <http://www.ncbi.nlm.nih.gov/geo/> under GSE10255 and GSM258912--GSM259072.
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ABC

:   ATP-binding cassette

ALL

:   childhood acute lymphoblastic leukemia

DFS

:   disease-free survival

FDR

:   false discovery rate

GO--BP

:   Gene Ontology--biological process

HDMTX

:   high-dose methotrexate

HR

:   hazard ratio

MTX

:   methotrexate

MTXPG

:   methotrexate polyglutamate

WBC%~drop~

:   percent WBC change

WBC

:   white blood cell count

WBCΔ~Day3~

:   MTX response as defined by the WBC residual based on the linear regression of log(WBC~PRE~) change to log(WBC~Day3~)

WBC~Day3~

:   peripheral WBC count on day 3 following start of HDMTX treatment

WBC~PRE~

:   peripheral WBC count pretreatment
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